From €3185EUR$3,500USD£2,731GBP
- Report
- March 2024
- 100 Pages
North America
From €3140EUR$3,450USD£2,692GBP
- Report
- August 2022
- 118 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2024
- 210 Pages
Global
From €3868EUR$4,250USD£3,316GBP
- Report
- May 2022
- 84 Pages
Europe
From €3413EUR$3,750USD£2,926GBP
- Report
- May 2022
- 95 Pages
Asia Pacific
From €3413EUR$3,750USD£2,926GBP
- Report
- April 2022
- 95 Pages
North America
From €3413EUR$3,750USD£2,926GBP
- Report
- November 2023
- 276 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- April 2023
- 200 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- September 2023
- 140 Pages
Global
From €3275EUR$3,599USD£2,808GBP
- Report
- February 2024
- 200 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- November 2023
- 130 Pages
Asia Pacific
From €3640EUR$4,000USD£3,121GBP
- Report
- March 2024
- 86 Pages
Global
From €6366EUR$6,995USD£5,458GBP
- Report
- May 2022
- 84 Pages
North America
From €1365EUR$1,500USD£1,170GBP
- Report
- September 2021
- 152 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- November 2020
- 450 Pages
Global
From €4459EUR$4,900USD£3,823GBP
- Report
- November 2021
- 747 Pages
Global
From €3640EUR$4,000USD£3,121GBP

Kadcyla is an oncology drug used to treat certain types of breast cancer. It is a targeted therapy that works by blocking the HER2 protein, which is found in some types of breast cancer cells. Kadcyla is administered intravenously and is used in combination with other treatments such as chemotherapy and radiation. It is approved for use in the United States, Europe, and other countries.
Kadcyla is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, such as ovarian and lung cancer. The drug is also being studied for its potential to reduce the risk of recurrence in patients who have already been treated for breast cancer.
The Kadcyla market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as Roche, Novartis, and Pfizer are all involved in the development and marketing of Kadcyla. Other companies such as Merck, AstraZeneca, and Eli Lilly are also involved in the development and marketing of the drug. Show Less Read more